Long-acting insulin analogs versus neutral protamine hagedorn insulin and the risk of severe hypoglycemia among patients in type 2 diabetes in the United Kingdom

被引：0
|
作者：
Brunetti, Vanessa C. [1 ]
Filion, Kristian [2 ]
Yu, Oriana Hoi Yun [2 ]
Platt, Robert [2 ]
机构：
[1] McGill, Dept Epidemiol Biostatist & Occupat Hlth, Montreal, PQ, Canada
[2] McGill Univ, Montreal, PQ, Canada
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2022年 / 31卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
267
引用
收藏
页码：114 / 114
页数：1
相关论文
共 50 条
  • [1] Severe Hypoglycemia Risk With Long-Acting Insulin Analogs vs Neutral Protamine Hagedorn Insulin
    Bradley, Marie C.
    Chillarige, Yoganand
    Lee, Hana
    Wu, Xiyuan
    Parulekar, Shruti
    Muthuri, Stella
    Wernecke, Michael
    MaCurdy, Thomas E.
    Kelman, Jeffrey A.
    Graham, David J.
    JAMA INTERNAL MEDICINE, 2021, 181 (05) : 598 - 607
  • [2] THE UTILISATION AND SWITCHING RATES OF NEUTRAL PROTAMINE HAGEDORN (NPH) INSULIN AND LONG-ACTING INSULIN ANALOGS IN PATIENTS WITH TYPE 2 DIABETES IN THE UNITED KINGDOM
    Brunetti, V. C.
    Yu, O. H. Y.
    Platt, R. W.
    Filion, K. B.
    VALUE IN HEALTH, 2020, 23 : S512 - S512
  • [3] Comparative Effectiveness of Long-Acting Insulin Analogs and Neutral Protamine Hagedorn (nph) Insulin for the Reduction of Major Adverse Cardiovascular Events Among Patients With Type 2 Diabetes
    Brunetti, Vanessa C. C.
    Yu, Oriana H.
    Platt, Robert W.
    Filion, Kristian B.
    CIRCULATION, 2021, 144
  • [4] Long-acting insulin analogs versus intermediate-acting insulin and the risk of major adverse cardiovascular events among patients with type 2 diabetes in the United Kingdom
    Brunetti, Vanessa C.
    Yu, Oriana
    Platt, RobertW
    Filion, Kristian B.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 104 - 104
  • [5] Basal insulin analogs versus neutral protamine hagedorn for type 2 diabetics
    Bartal, Michal Fishel
    Ward, Clara
    Refuerzo, Jerrie S.
    Ashimi, Sunbola S.
    Joycelyn, Cornthwaite A.
    Chen, Han-Yang
    Chauhan, Suneet P.
    Sibai, Baha M.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2019, 220 (01) : S273 - S274
  • [6] Basal Insulin Analogs versus Neutral Protamine Hagedorn for Type 2 Diabetics
    Fishel Bartal, Michal
    Ward, Clara
    Refuerzo, Jerrie S.
    Ashimi, Sunbola S.
    Joycelyn, Cornthwaite A.
    Chen, Han-Yang
    Chauhan, Suneet P.
    Sibai, Baha M.
    AMERICAN JOURNAL OF PERINATOLOGY, 2020, 37 (01) : 30 - 36
  • [7] Long-acting insulin versus neutral protamine hagedorn on diabetes of pregnancy outcomes: a meta-analysis of RCTs
    McLaren, Rodney A., Jr.
    Al-Kouatly, Huda B.
    Berghella, Vincenzo
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2023, 228 (01) : S384 - S385
  • [8] The utilization of long-acting insulin analogues and intermediate-acting NPH insulin among patients with type 2 diabetes in the United Kingdom
    Brunetti, Vanessa C.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 404 - 404
  • [9] The utilisation of long-acting insulin analogues and intermediate-acting insulin in patients with type 2 diabetes in the United Kingdom
    Brunetti, V. C.
    Yu, O. H. Y.
    Platt, R. W.
    Filion, K. B.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S146 - S146
  • [10] The association of long-acting insulin analogue use versus neutral protamine Hagedorn insulin use and the risk of major adverse cardiovascular events among individuals with type 2 diabetes: A population-based cohort study
    Brunetti, Vanessa C.
    Yu, Oriana Hoi Yun
    Platt, Robert W.
    Filion, Kristian B.
    DIABETES OBESITY & METABOLISM, 2022, 24 (11): : 2169 - 2181
12345